A Practical Guide to Accessing OPZELURA® (ruxolitinib) Cream 1.5%

You leave the dermatologist with a prescription for OPZELURA (ruxolitinib) cream 1.5%. It’s the first FDA-approved treatment for repigmentation (the return of skin color) in those with nonsegmental vitiligo 12 years of age and older—and the start of something new for you and your treatment journey with vitiligo. Maybe it took you months to get this appointment, or maybe you’ve been thinking about OPZELURA for a while and today was the day you decided to bring it up. Either way, you walk out of the appointment with a prescription. And then the reality of the next steps sinks in.

The insurance process. The prior authorization. The cost questions you weren’t sure how to ask. How does it all work? What’s a prior authorization, again? What if it gets denied? For a lot of people in our community, this is the part that feels the most overwhelming—not because they’re not ready to move forward, but because the system isn’t exactly designed to make it easy.

The good news? There are resources to help you navigate this. We’re going to walk you through the process and introduce you to a few of those resources—because knowing your options can make this process feel more manageable.

The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended. OPZELURA has warnings for risks that include serious infections, increased risk of death, cancer and immune system problems, increased risk of major cardiovascular events, and blood clots.

What Prior Authorization Means

OPZELURA is a prescription medication, and the cost can vary widely depending on your insurance plan. Many insurance companies require something called prior authorization (or PA) before approving coverage. Prior authorization is essentially your insurer’s way of confirming that a treatment is medically appropriate for your specific situation before they agree to pay for it.

Your dermatologist’s office typically handles the PA submission on your behalf, but it can take time, and it often requires follow-up. Coverage decisions usually hinge on three things: your diagnosis, how much of your body surface area is affected, and what treatments you’ve tried before.

That last point is worth paying attention to now, before you even begin the process. Keeping a record of treatments you’ve previously tried—even if they didn’t work, even if it was years ago—can help support your approval. If you don’t have that information handy, it’s worth pulling together before your dermatologist submits.

How to Navigate Insurance Denials

If your insurance denies coverage for OPZELURA, don’t panic. Many first-time requests are denied automatically. A denial is often the beginning of the process, not the end. It can be a frustrating reality of navigating insurance coverage for vitiligo treatments, but it’s not a reflection of whether you’re a good candidate for the medication.

If your coverage is denied, here’s a path forward:

Step 1: Request an appeal. Ask your dermatologist to submit an appeal or a reconsideration request. This may include additional documentation or a letter of medical necessity. Your dermatologist’s office should be familiar with this process.

Step 2: Call your insurance company. Ask specifically why the request was denied. Write down everything: the date, the name of the representative you spoke with, and the exact reason given. That information will be useful when your dermatologist submits the appeal.

Step 3: Stay persistent. Some approvals happen after one or two appeals. Keep following up with your provider’s office and stay in communication throughout.

Remember: Access can take time and often requires persistence. You may not be doing anything wrong if it doesn’t go smoothly the first time.

Discussing OPZELURA Access with Your Dermatologist

Sometimes the hardest part of ensuring a successful dermatology appointment is knowing what questions to ask. One of the things that can make this process feel less daunting is having a few specific questions ready—not a script, but a starting point that take some of the guesswork out of the conversation.

Some language that might help you speak with your doctor:

How does the insurance process work, and what can I expect?
What does the prior authorization process look like for me specifically?
If my insurance requires documentation, what information will be most helpful for the submission?
If the first request is denied, what is the appeal process like?
Are there patient support programs I should know about before we get started?

You don’t need to walk into your appointment knowing all the answers—but asking the right questions is the right place to start.

OPZELURA OnTrac™—Support for this Process

OPZELURA OnTrac is a support program designed specifically for those who have been prescribed OPZELURA. If the insurance navigation piece feels like a lot to manage on your own, this program exists to help.

A few ways OPZELURA OnTrac can help:

Understand your insurance coverage
Find savings options
Understand how to use the medication
Ongoing support throughout your time on treatment

If you’ve just received a prescription and aren’t sure where to start with coverage, this is a resource worth knowing about.

IncyteCARES^®: If Cost Is the Barrier

IncyteCARES is a separate support program that may help those eligible access OPZELURA regardless of their insurance situation. For those with commercial insurance, IncyteCARES may offer copay assistance to reduce out-of-pocket costs. For those who are uninsured or underinsured, the program may be able to provide free medication. It can also help with benefits verification and connect you with resources to better understand your treatment options.

Cost shouldn’t stand between you and a treatment conversation with your dermatologist. If you’re not sure whether you qualify, it’s worth looking into.

The Bottom Line—And a Free Guide

Navigating the insurance process for prescription treatments like OPZELURA can feel overwhelming—the paperwork, the phone calls, the waiting, the advocating. That’s real. Your dermatologist’s office, OPZELURA OnTrac, and IncyteCARES, are resources available to support you along the way.

For a more comprehensive guide to OPZELURA—including what it is and how it works, real stories from the community, what to expect, and a community Q&A—sign up to get our guide.

*Erika has not been prescribed Opzelura

This guide was created in partnership with Incyte. The information in this guide is not a substitute for a visit or consultation with a healthcare professional. Please consult a healthcare professional if you have any questions.

INDICATION AND USAGE

OPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older.

The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION

OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors, which are medicines that affect your immune system and can lower your ability to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while using OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death due to any reason (all causes) and major cardiovascular events: Increased risk of death and major cardiovascular events (eg, heart attack or stroke) has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking JAK inhibitors by mouth, especially current or past smokers.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. People taking JAK inhibitors by mouth have reported lymphoma and other cancers and are at higher risk of certain cancers including lymphoma and lung cancer, especially if they have ever smoked. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment. Limit the amount of time you spend in the sun, wear protective clothing and use a broad-spectrum sunscreen.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. DVT and PE have happened more often in people taking JAK inhibitors by mouth who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia, lymphopenia, leukopenia). Your healthcare provider may do a blood test to check your blood cell counts during your treatment and may stop your treatment if signs or symptoms of low blood cell counts happen.

Potential risks from Janus kinase (JAK) inhibition: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides. Low blood sugar in people with diabetes has happened after taking JAK inhibitors by mouth.

Before starting OPZELURA, tell your healthcare provider if you:

have an infection, are being treated for one, or have had an infection that does not go away or keeps coming back
have diabetes, chronic lung disease, HIV, or a weak immune system
have TB or have been in close contact with someone with TB
have had shingles (herpes zoster)
have or have had hepatitis B or C
live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common
think you have an infection or have symptoms of an infection such as: fever, sweating, or chills, muscle aches, cough or shortness of breath, blood in your phlegm, weight loss, warm, red, or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or urinating more often than usual, feeling very tired

have ever had any type of cancer, or are a current or past smoker
have had a heart attack, other heart problems, or a stroke
have had blood clots in the veins of your legs or lungs in the past
have or have had low white or red blood cell counts
are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463 or www.opzelura.pregnancy.incyte.com. This registry is intended to collect information about the health of you and your baby
are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose

After starting OPZELURA:

Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
Get emergency help right away if you have any symptoms of a heart attack, blood clot, or stroke while using OPZELURA, including:
discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw, or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
weakness in one part or on one side of your body
slurred speech
swelling, pain, or tenderness in one or both legs

Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath, or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever.

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.

OPZELURA, the OPZELURA logo, Incyte, and IncyteCARES are registered trademarks and OPZELURA On Trac is a trademark of Incyte.

Erika Page

A patient advocate, editor, and sought-after leader within the vitiligo community, Erika Page is also the Founder and CEO of Living Dappled. After getting vitiligo at the age of seven, she lost 100% of her skin’s pigment over 25 years. She fought her own mental and emotional battle to overcome her insecurities and embrace the skin she was in and today seeks to help other women reclaim their lives with this condition.